CLOs on the Move


 
DMC is leading the low cost sustainable transformation of multiple product markets.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.dmcbio.com
  • 2477 55th St, Suite 120
    Boulder, CO USA 80303
  • Phone: N/A

Executives

Name Title Contact Details

Similar Companies

Essentia Biosystems

Essentia Biosystems is a Mountain View, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Keros Therapeutics

Keros Therapeutics is dedicated to the discovery and development of novel therapeutics for neuromuscular diseases

Achaogen

Achaogen is a clinical-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant, or MDR, gram-negative infections. We are anchored in our work by our key values of integrity, accountability, transparency, scientific rigor and drive. We pride ourselves in creating a work community that is patient-centric, scientifically driven, supportive, and collaborative, and that encourages the diversity of thought leading to great innovation. We are always excited to add people to our dynamic team who thrive in our community and who are driven and motivated to transform the lives of patients.

Spinal Dimensions

Spinal Dimensions is a Albany, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Allena Pharmaceuticals

Allena Pharmaceuticals is dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic disorders that affect the kidney. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease. Allena`s proprietary technological approach enables the design, formulation and delivery of non-absorbed and stable enzymes orally and in sufficient doses for activity in the GI tract. This approach utilizes the GI tract to degrade metabolites, such as oxalate and urate, reducing plasma and urine levels, and in turn, reducing their disease burden on the kidney over time.